NEW YORK (GenomeWeb News) – Israeli plant genomics firm Evogene today reported a 5 percent increase in revenues for its third quarter.

Evogene said that revenues for the three months ended Sept. 30 totaled $4.2 million, up from $4.0 million a year ago. Its comprehensive loss for the period rose to $2.3 million, or $.06 per share, from a comprehensive loss of $1.0 million, or $.03 per share, in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.